Ordering
Available Variants5 mg
CHA.70890-5mg
Price
€225.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.70890-5mg | €225.60 |
≥98% (HPLC), solid
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C14H17N3O3S · HCl · xH2O |
|---|---|
| CAS Number | 155558-32-0 |
| Molecular Weight | 343.83 (anhydrous basis) |
| NACRES | NA.77 |
| PubChem Substance ID | 24724499 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD06411567 |
| Assay | ≥98% (HPLC) |
| Form | solid |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS07
 GHS07
|
|---|---|
| signalword | Warning |
| hcodes | H302 |
| pcodes | P264 - P270 - P301 + P312 - P501 |
| Hazard Classifications | Acute Tox. 4 Oral |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | dust mask type N95 (US), Eyeshields, Faceshields, Gloves |
Technical Overview & Applications Use-case context
Hydroxyfasudil hydrochloride hydrate, with a CAS number of 155558-32-0, is a potent rho-kinase inhibitor that has been extensively studied for its therapeutic potential in various cardiovascular and cerebrovascular disorders. The compound exhibits a high degree of selectivity for rho-kinase, thereby inhibiting the enzymes activity and leading to vasodilation and improved blood flow. Research has demonstrated that hydroxyfasudil hydrochloride hydrate possesses a favorable pharmacokinetic profile, characterized by rapid absorption and a relatively long half-life. Additionally, the compound has been shown to be well-tolerated in preclinical and clinical studies, with a low incidence of adverse effects. As a result, hydroxyfasudil hydrochloride hydrate is considered a promising candidate for the treatment of conditions such as cerebral vasospasm, hypertension, and heart failure, and further investigation is warranted to fully elucidate its therapeutic potential.
